New drug cocktail targets Hard-to-Treat lung cancer
NCT ID NCT07382726
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a combination of two drugs—izalontamab brengitecan (given by IV) and adagrasib (a pill)—in 18 adults with advanced KRAS G12C-mutant non-small cell lung cancer that has stopped responding to other treatments. The main goal is to check safety and side effects. If the combination proves safe, it may lead to larger studies to see if it can help control the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
izalontamab brengitecan and adagrasib
What this could lead to
If it works, this combination could offer a new treatment option for people with a specific type of lung cancer that has stopped responding to current targeted therapies.
What could go wrong
This is a very early Phase 1 trial with only 18 participants, so it is too soon to know if the combination is safe or effective. The cancer may still grow despite treatment, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact